CL2021001575A1 - Pirazolopirimidinas sustituidas y purinas sustituidas y su uso como inhibidores de proteasa procesadora específica de ubiquitina 1 (usp1) - Google Patents

Pirazolopirimidinas sustituidas y purinas sustituidas y su uso como inhibidores de proteasa procesadora específica de ubiquitina 1 (usp1)

Info

Publication number
CL2021001575A1
CL2021001575A1 CL2021001575A CL2021001575A CL2021001575A1 CL 2021001575 A1 CL2021001575 A1 CL 2021001575A1 CL 2021001575 A CL2021001575 A CL 2021001575A CL 2021001575 A CL2021001575 A CL 2021001575A CL 2021001575 A1 CL2021001575 A1 CL 2021001575A1
Authority
CL
Chile
Prior art keywords
usp1
substituted
ubiquitin
inhibitors
specific processing
Prior art date
Application number
CL2021001575A
Other languages
English (en)
Inventor
Jehrod Burnett Brenneman
Elsa Beyer Krall
Michael Schlabach
Andrew Alistair Wylie
Original Assignee
Ksq Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ksq Therapeutics Inc filed Critical Ksq Therapeutics Inc
Publication of CL2021001575A1 publication Critical patent/CL2021001575A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La presente descripción proporciona compuestos que tienen la Fórmula I: y las sales y solvatos farmacéuticamente aceptables de estos, donde X1, X2, X11, X12, R1, R3, R5, R5', R6 y R7 se definen como se indica en la memoria descriptiva. La presente descripción también hace referencia al uso de compuestos de Fórmula I para inhibir una proteína USP1 y/o para tratar un trastorno que responde a la inhibición de proteínas USP1 y la actividad de USP1. Los compuestos de la presente descripción son especialmente útiles para el tratamiento del cáncer.
CL2021001575A 2018-12-20 2021-06-16 Pirazolopirimidinas sustituidas y purinas sustituidas y su uso como inhibidores de proteasa procesadora específica de ubiquitina 1 (usp1) CL2021001575A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862783014P 2018-12-20 2018-12-20
US201962799423P 2019-01-31 2019-01-31
US201962857986P 2019-06-06 2019-06-06
US201962868616P 2019-06-28 2019-06-28
US201962946263P 2019-12-10 2019-12-10

Publications (1)

Publication Number Publication Date
CL2021001575A1 true CL2021001575A1 (es) 2022-06-03

Family

ID=71100912

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021001575A CL2021001575A1 (es) 2018-12-20 2021-06-16 Pirazolopirimidinas sustituidas y purinas sustituidas y su uso como inhibidores de proteasa procesadora específica de ubiquitina 1 (usp1)

Country Status (14)

Country Link
US (2) US11485736B2 (es)
EP (1) EP3897652A4 (es)
JP (1) JP2022511515A (es)
KR (1) KR20210105887A (es)
CN (1) CN113164485A (es)
AU (1) AU2019405925A1 (es)
BR (1) BR112021010715A2 (es)
CA (1) CA3122108A1 (es)
CL (1) CL2021001575A1 (es)
CO (1) CO2021009078A2 (es)
IL (1) IL284050A (es)
MX (1) MX2021007179A (es)
SG (1) SG11202106232TA (es)
WO (1) WO2020132269A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022511515A (ja) 2018-12-20 2022-01-31 ケーエスキュー セラピューティクス， インコーポレイテッド 置換されたピラゾロピリミジン及び置換されたプリンならびにユビキチン特異的プロセシングプロテアーゼ１（ｕｓｐ１）阻害剤としてのそれらの使用
EP4090332A4 (en) * 2020-01-15 2024-02-14 Ksq Therapeutics Inc COMPOSITIONS OF SUBSTITUTED PYRAZOLOPYRIMIDINES AND THEIR USES
IL295149A (en) * 2020-02-14 2022-09-01 Ksq Therapeutics Inc Therapeutic combinations containing ubiquitin-specific processing protease 1 (usp1) inhibitors and poly(adp-ribose) polymerase (parp) inhibitors
WO2021247606A1 (en) * 2020-06-02 2021-12-09 KSQ Therapeutics, Inc. Nitrogen-containing fused bicyclic compounds and their use as ubiquitin-specific-processing protease 1 (usp1) inhibitors
CN116615424A (zh) * 2020-10-30 2023-08-18 Ksq治疗公司 经取代的吡唑并嘧啶的固态形式和其用途
EP4291559A1 (en) * 2021-02-15 2023-12-20 Tango Therapeutics, Inc. Pyrrolo[3,2-d]pyrimidine compounds and methods of use in the treatment of cancer
JP2024511996A (ja) * 2021-03-17 2024-03-18 タンゴ セラピューティクス， インコーポレイテッド 抗がん剤としてのプリン誘導体
WO2022216820A1 (en) * 2021-04-07 2022-10-13 Forma Therapeutics, Inc. Inhibiting ubiquitin-specific protease 1 (usp1)
WO2022233263A1 (zh) * 2021-05-03 2022-11-10 山东轩竹医药科技有限公司 三并环类泛素特异性蛋白酶1抑制剂及其用途
WO2022253188A1 (en) * 2021-05-31 2022-12-08 Impact Therapeutics (Shanghai) , Inc Nitrogen-containing fused heteroaromatic bicyclic compounds as usp1 inhibitors and the use thereof
GB202114863D0 (en) 2021-10-18 2021-12-01 Syngenta Crop Protection Ag Improvements in or relating to organic compounds
CA3235663A1 (en) * 2021-10-19 2023-04-27 Impact Therapeutics (Shanghai), Inc. Substituted triazoloheteroaryl compounds as usp1 inhibitors and the use thereof
CN114031556B (zh) * 2021-11-08 2023-03-31 温州大学 一种绿色的一锅法制备5-氨基-n-芳基-3-芳基吡唑类化合物的合成方法
WO2023083286A1 (en) * 2021-11-12 2023-05-19 Insilico Medicine Ip Limited Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof
CA3235603A1 (en) * 2021-11-12 2023-05-19 Insilico Medicine Ip Limited Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof
CN114181237B (zh) * 2021-12-01 2024-02-23 上海凌凯医药科技有限公司 一种1-异丙基吡唑-5-硼酸频那醇酯的合成方法
CA3237961A1 (en) * 2021-12-09 2023-06-15 Jeremy Clinton Wilt Methods of preparing substituted pyrazolopyrimidines
WO2023143424A1 (zh) * 2022-01-27 2023-08-03 四川海思科制药有限公司 一种氮杂并环衍生物及其在医药上的应用
WO2023148643A1 (en) * 2022-02-03 2023-08-10 Aurigene Oncology Limited Fused bicyclic heterocyclyl compounds as usp1 inhibitors
TW202342475A (zh) * 2022-02-18 2023-11-01 大陸商四川海思科製藥有限公司 一種吡唑並吡啶衍生物及其在醫藥上的應用
WO2023196955A1 (en) * 2022-04-08 2023-10-12 KSQ Therapeutics, Inc. Therapeutic combinations comprising ubiquitin- specific-processing protease 1 (usp1) inhibitors and chemotherapy agents
CN116496252A (zh) * 2022-04-29 2023-07-28 江苏亚虹医药科技股份有限公司 嘧啶类化合物、其制备方法及其医药用途
WO2023250084A1 (en) * 2022-06-23 2023-12-28 Forma Therapeutics, Inc. Usp1 inhibitors and uses thereof
US20240092779A1 (en) * 2022-06-29 2024-03-21 Zentaur Therapeutics Usa Inc. Usp1 inhibitors and uses thereof
WO2024022266A1 (en) * 2022-07-25 2024-02-01 Guangdong Newopp Biopharmaceuticals Co., Ltd. Heteroaryl compounds as inhibitors of usp1
WO2024022519A1 (zh) * 2022-07-28 2024-02-01 先声再明医药有限公司 杂环并嘧啶类化合物及其应用
WO2024032647A1 (zh) * 2022-08-09 2024-02-15 上海济煜医药科技有限公司 含氮杂环化合物作为泛素-特异性蛋白酶1抑制剂的制备方法、应用及其用途
WO2024041634A1 (zh) * 2022-08-26 2024-02-29 先声再明医药有限公司 三环类化合物及其应用
WO2024046471A1 (zh) * 2022-09-02 2024-03-07 上海齐鲁制药研究中心有限公司 Usp1抑制剂
WO2024051795A1 (zh) * 2022-09-09 2024-03-14 正大天晴药业集团股份有限公司 用作泛素-特异性蛋白酶抑制剂的取代嘌呤酮衍生物
WO2024061213A1 (zh) * 2022-09-20 2024-03-28 正大天晴药业集团股份有限公司 用作泛素-特异性蛋白酶抑制剂的羰基稠合杂环衍生物
WO2024078436A1 (zh) * 2022-10-09 2024-04-18 海南先声再明医药股份有限公司 杂环并嘧啶类化合物、药物组合物及其应用
WO2024086790A1 (en) 2022-10-21 2024-04-25 Exelixis, Inc. 4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-c]PYRIDINE COMPOUNDS AND DERIVATIVES AS USP1 INHIBITORS
CN116768906B (zh) * 2023-05-29 2024-04-09 遵义医科大学珠海校区 一种三并环化合物及其制备方法和应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
DK0786469T3 (da) 1990-06-11 2006-07-10 Gilead Sciences Inc Nukleinsyreligander
AU672790B2 (en) 1992-07-15 1996-10-17 Novartis Ag Variants of parathyroid hormone and its fragments
AU3204895A (en) 1995-02-01 1996-08-21 University Of Massachusetts Medical Center Methods of selecting a random peptide that binds to a target protein
JP2001512560A (ja) 1996-10-08 2001-08-21 ユー―ビスイス ベスローテン フェンノートシャップ 標的に対し特異的な親和性を有するペプチドおよびタンパク質の選択のための方法および手段
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
EP1831225A2 (en) 2004-11-19 2007-09-12 The Regents of the University of California Anti-inflammatory pyrazolopyrimidines
WO2007149484A2 (en) 2006-06-20 2007-12-27 Dana-Farber Cancer Institute Inhibitors of usp1 deubiquitinating enzyme complex
WO2008066624A2 (en) 2006-10-20 2008-06-05 Dana-Farber Cancer Institute Dna damage repair inhibitors and methods for treating cancer
US7964356B2 (en) 2007-01-16 2011-06-21 Somalogic, Inc. Method for generating aptamers with improved off-rates
DK2209786T3 (da) * 2007-10-05 2013-06-03 Verastem Inc Pyrimidinsubstituerede purinderivater
US8598184B2 (en) 2008-03-03 2013-12-03 Tiger Pharmatech Protein kinase inhibitors
WO2009157196A1 (ja) * 2008-06-25 2009-12-30 武田薬品工業株式会社 アミド化合物
GB0917934D0 (en) * 2009-10-13 2009-11-25 Syngenta Ltd Herbicidal compounds
CA2797719C (en) * 2010-04-30 2019-11-26 Dana-Farber Cancer Institute, Inc. Small molecule inhibitors of usp1 deubiquitinating enzyme activity
US9802904B2 (en) 2012-12-28 2017-10-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibitors of the USP1/UAF1 deubiquitinase complex and uses thereof
JP2016537028A (ja) 2013-11-18 2016-12-01 クリスパー セラピューティクス アーゲー Ｃｒｉｓｐｒ−ｃａｓシステムの材料及び方法
KR101766194B1 (ko) 2015-08-07 2017-08-10 한국과학기술연구원 RET 키나아제 저해제인 신규 3-(이속사졸-3-일)-피라졸로[3,4-d]피리미딘-4-아민 화합물
US10189841B2 (en) * 2015-11-20 2019-01-29 Forma Therapeutics, Inc. Purinones as ubiquitin-specific protease 1 inhibitors
JP2022511515A (ja) 2018-12-20 2022-01-31 ケーエスキュー セラピューティクス， インコーポレイテッド 置換されたピラゾロピリミジン及び置換されたプリンならびにユビキチン特異的プロセシングプロテアーゼ１（ｕｓｐ１）阻害剤としてのそれらの使用
EP4291559A1 (en) 2021-02-15 2023-12-20 Tango Therapeutics, Inc. Pyrrolo[3,2-d]pyrimidine compounds and methods of use in the treatment of cancer

Also Published As

Publication number Publication date
CA3122108A1 (en) 2020-06-25
AU2019405925A1 (en) 2021-07-29
CO2021009078A2 (es) 2021-10-29
BR112021010715A2 (pt) 2021-11-16
US20210115049A1 (en) 2021-04-22
US11787813B2 (en) 2023-10-17
EP3897652A4 (en) 2022-09-14
IL284050A (en) 2021-08-31
US11485736B2 (en) 2022-11-01
CN113164485A (zh) 2021-07-23
EP3897652A1 (en) 2021-10-27
KR20210105887A (ko) 2021-08-27
TW202039501A (zh) 2020-11-01
US20230203046A1 (en) 2023-06-29
WO2020132269A1 (en) 2020-06-25
MX2021007179A (es) 2021-09-28
SG11202106232TA (en) 2021-07-29
JP2022511515A (ja) 2022-01-31

Similar Documents

Publication Publication Date Title
CL2021001575A1 (es) Pirazolopirimidinas sustituidas y purinas sustituidas y su uso como inhibidores de proteasa procesadora específica de ubiquitina 1 (usp1)
CL2020002146A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer.
ECSP19011216A (es) Inhibidores de piridopyrimdinona cdk2/4/6
ECSP18094983A (es) Derivados de pirazol como inhibidores de la calicreína plasmática
CL2017000469A1 (es) Derivados de tetrahidronaftaleno que inhiben la proteina mcl-1
CO2022008091A2 (es) Inhibidores de kras g12c
CL2019001674A1 (es) Inhibidores de imidazopirazina de tirosina quinasa de bruton.
CO2017011038A2 (es) Derivados de (s)-2-((2-oxooxazolidin-3-il)-5,6-dihidrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-il)amino)amidas como inhibidores de pi3kca”
GT201600123A (es) Inhibidores de syk
ECSP18083519A (es) Inhibidores de bromodominios
EA201890307A1 (ru) Индазольные и азаиндазольные соединения как ингибиторы irak-4
CO2020015758A2 (es) Compuestos de purinona y su uso en el tratamiento del cáncer
CR20150264A (es) Compuestos biciclicos de urea, tiourea, guanidina y cianoguanidina utiles para el tratamiento del dolor
UY36207A (es) Inhibidores de la syk
ECSP21038390A (es) Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de su uso como inhibidores de la cinasa atr
PE20181346A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cancer
CO2019010559A2 (es) Composiciones y compuestos terapéuticos y métodos para utilizarlos
CO2022000266A2 (es) Inhibidores de enzimas
CL2021000844A1 (es) Compuestos de indolinona para uso como inhibidores de map4k1
CL2017000845A1 (es) Inhibidores de gingipaina de lisina
DOP2013000207A (es) Derivados de piridinilo y pirazinil-metiloxi-arilo utiles como inhibidores de la tirosina cinasa del bazo (syk)
CL2023002223A1 (es) Inhibidores de cdk2 y métodos de uso de los mismos
CL2021002521A1 (es) Compuestos heteocíclicos y sus usos.
CO2022000270A2 (es) Inhibidores de enzimas
CL2022000214A1 (es) Inhibidores de enzimas